CT Colonography Outperforms FIT for Colorectal Cancer Screening

If you work in abdominal imaging, this one is worth your attention. A study published in Radiology comparing CT colonography (CTC) and fecal immunochemical testing (FIT) for colorectal cancer screening has produced results that strongly favor CTC, and an accompanying editorial is calling for a fundamental shift in how we position these screening tools.

The Key Finding: CTC Catches Cancer Earlier

Italian researchers compared CTC and FIT screening cohorts and found that CTC detected advanced adenomas at a rate of 91% vs 79.2% for FIT. But the timing data is even more striking: 88.9% of cancers in the CTC group were detected at initial screening, compared to just 41.4% in the FIT group.

Most cancers in the FIT cohort were identified after the initial screening round, resulting in later-stage diagnoses. Every single stage IV cancer in the study was found in the FIT group. Let that sink in.

CTC vs Colonoscopy: Closer Than You Think

The editorial, co-authored by Drs. Pietryga (Mayo Clinic) and Kim (University of Wisconsin), goes further. Citing the U.S. Preventive Services Task Force, they note that CTC performance is equivalent to colonoscopy for detecting polyps 6mm or greater, which covers the vast majority of clinically relevant precancerous lesions.

Patients with negative CTC results avoid colonoscopy entirely, eliminating perforation and sedation risks. For patients who are hesitant about invasive screening, CTC offers a genuinely comparable alternative.

The Participation Problem

CTC is not without challenges. The study showed lower participation rates for CTC (26.6%) compared to FIT (64.9%). The reason is straightforward: FIT is a simple stool test done at home with no bowel prep. CTC still requires preparation and a visit to a clinical setting.

But the editorial argues that focusing on participation rates alone is misleading. A test that finds cancer too late is not a better test just because more people take it. The goal is not maximum screening participation, it is maximum cancer prevention.

Why Indian Radiologists Should Pay Attention

India is seeing a rising incidence of colorectal cancer, particularly in urban populations. The country lacks the colonoscopy infrastructure to screen at scale, which makes CTC especially relevant. With CT scanners already installed in most urban hospitals and many tier-2 centers, CTC offers a way to expand screening capacity without requiring the specialized endoscopy suites and sedation infrastructure that colonoscopy demands.

Radiology departments that build CTC expertise now are positioning themselves at the center of cancer prevention, not just detection.

The Bottom Line

CTC detects more cancers, detects them earlier, and performs comparably to colonoscopy for clinically significant lesions. The participation gap is real but should not overshadow the diagnostic superiority. For radiologists, CTC is not just another imaging modality. It is a screening tool that saves lives, and the data increasingly says it does it better than the alternatives.